Document is current
Any future updates will be listed below
-
Authors
Shaulov, Adir
Rodin, Gary
Popovic, Gordana
Caraiscos, Valerie B.
Le, Lisa W.
Rydall, Anne
Schimmer, Aaron D.
Zimmermann, Camilla https://orcid.org/0000-0003-4889-0244
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (84317)
Canadian Cancer Society (702603)
Princess Margaret Cancer Foundation (NA)
Ontario Ministry of Health and Long-Term Care (NA)
- License Information
-
More Information
Article History
Received: 16 September 2018
Accepted: 28 November 2018
First Online: 8 December 2018
Compliance with ethical standards
: This study received approval from the University Health Network (UHN) Research Ethics Board (REB #06-0387-CE). All study participants provided written informed consent.
: A.D. Schimmer reports personal fees and grants outside this submitted work from Novartis, Takeda Pharmaceuticals, Aeglea Pharmaceuticals, and Trillium Therapeutics. The remaining authors declare no conflicts of interest.
: Findings were presented in part at the Multinational Association of Supportive Care in Cancer (MASCC)/ISOO 2017 Annual Meeting on Supportive Care in Cancer, Washington, DC, USA, June 22–24, 2017 (e-poster presentation); early/preliminary findings were presented at the 20th International Congress on Palliative Care, Montreal, Quebec, Canada, September 9–12, 2014 (poster presentation); the MASCC/ISOO 2014 Annual Meeting on Supportive Care in Cancer, Miami, Florida, United States, June 26–28, 2014 (oral presentation); the Hospice Palliative Care Ontario Annual Conference, Toronto, Ontario, Canada, April 27–29, 2014 (oral presentation); and the 9th Annual Advanced Learning in Palliative Medicine Conference, Vancouver, British Columbia, Canada, June 13–15, 2013 (oral presentation).
